Home
On-Demand
Industrie
FAQ
Login MyUpdate
Home
On-Demand
Industrie
FAQ
Login MyUpdate
Schlagwort
Dostarlimab
Ovarialkarzinom – Systemtherapie
Ovarialkarzinom – Systemtherapie
1st Line Immuntherapie
/
Apatinib
/
bevacizumab
/
BRCA
/
Dostarlimab
/
DUO-O
/
endometrioiden „NSMP“ Ovarialkarzinom
/
ER-Expression
/
fortgeschrittenen Ovarialkarzinoms
/
Fuzuloparib
/
Genomic Instability Score (GIS)
/
ICON8B
/
KELIM
/
KEYNOTE-B96
/
NAPISTAR-01
/
neoadjuvanter Chemotherapie
/
Niraparib
/
Olaparib
/
PAOLA-1-Studie
/
PARPi-Erhaltungsgherapie
/
Pembrolizumab
/
Platin-haltige Chemotherapie
/
Primärtherapie
/
Rezidivtherapie
/
ROSELLA
Genitalkarzinome
Genitalkarzinome
bevacizumab
/
Dostarlimab
/
DUO-O-Studie
/
Durvalumab
/
Endometriumkarzinom
/
Genitalkarzinome
/
INTERLACE-Studie
/
MIRASOL- Studie
/
NRG GY018-Studie
/
Olaparib
/
Ovarialkarzinom
/
Pembrolizumab
/
RUBY-Studie
/
SHAPE-Studie
/
Zervixkarzinom
Gastrointestinale Onkologie
Gastrointestinale Onkologie
DANTE-Studie
/
Dostarlimab
/
Futibatinib
/
Ipilimumab
/
KEYNOTE-811-Studie
/
Magenkarzinom
/
NALIRIFOX
/
NeoAegis-Studie
/
NEONAX-Studie
/
Ösophaguskarzinom
/
PREOPANC-2-Studie
/
PROSPECT-Studie
/
RAPIDO-Studie
/
Rektumkarzinom
/
Zolbetuximab
Kolorektale Tumore
Kolorektale Tumore
BRAF V600E
/
CAIRO-5
/
ctDNA
/
Destiny-CRC-02
/
Dostarlimab
/
FOXTROT
/
Fruquintinib
/
GALAXY
/
HER2+
/
HIPEC
/
Imuntherapie
/
Kolon perioperativ St. II & III
/
Kolorektal palliativ
/
Kolorektale Tumore
/
Konversionstherapie
/
KRAS G12C
/
MSI
/
MSI-Tumore
/
MSS-Tumore
/
neoadjuvante Chemotherapie
/
OCUM
/
OPERA
/
OPRA
/
PARADDIGM
/
PRODIGE-23
/
Radio-Chemotherapie
/
RAPIDO
/
Rektumkarzinom
/
Sintilimab
/
Standard-RChT
/
T4-Tumore
/
TNT
Endometriumkarzinom
Endometriumkarzinom
Brachytherapie
/
Carboplatin
/
Chemotherapie
/
Cisplatin
/
Dostarlimab
/
Endometriumkarzinom
/
GARNET-Studie
/
Karzinosarkom
/
Keynote-775-Studie
/
LAVH
/
Lenvatinib
/
Lymphadenektomie
/
MIC
/
Paclitaxel
/
TOTEM-Trial
